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Chronic exposure of humans to benzene causes acute myelogenous leukemia (AML). The studies
presented here were undertaken to determine whether benzene, or its reactive metabolite,
hydroquinone (HQ), affects differentiation of myeloblasts. Benzene or HQ administered to
C57BL/6J mice specifically induced granulocytic differentiation of myeloblasts. The ability of these
compounds to induce differentiation of the myeloblast was tested directly using the murine
interleukin 3 (IL-3)-dependent 32D.3 (G) myeloblastic cell line, and the human HL-60
promyelocytic leukemia cell line. We have previously shown that benzene treatment of HL-60
myeloblasts activates protein kinase C (PKC) and upregulates the 5-lipoxygenase (LPO) pathway
for the production of leukotriene D4 (LTD4), an essential effector of granulocytic differentiation.
Differentiation was prevented by sphinganine, a PKC inhibitor, and, as shown here, by LPO
inhibitors and LTD4 receptor antagonists. Benzene or HQ also induces differentiation in 32D.3 (G)
myeloblasts. Both compounds interact with cellular signaling pathways normally activated by
granulocyte colony stimulating factor (G-CSF) and can replace the requirement for G-CSF. While
IL-3 induces a growth response in 32D.3 (G) cells, G-CSF has been shown to provide both growth
and differentiation signals. Both HQ and LTD4 induce differentiation and synergize with IL-3 for
growth; however, neither supports growth in the absence of IL-3. Benzene, like HQ, also
provides a differentiation signal for 32D cells; however, it has no effect on their growth. Unlike
G-CSF, benzene, or LTD4, each of which stimulates terminal differentiation, HQ blocks
differentiation at the myelocyte stage, allowing only a small percentage of progenitors to proceed
to mature segmented granulocytes. Benzene- and G-CSF-induced differentiation were prevented
by the addition of either LPO inhibitors or LTD4 receptor antagonists, indicating that benzene, like
G-CSF, upregulates LTD4 production. Hydroquinone-induced differentiation was not affected by
the LPO inhibitors, but only by the specific receptor antagonists. Thus HQ appears to obviate the
requirement for LTD4 by activating the LTD4 receptor directly. - Environ Health Perspect
104(Suppl 6):1257-1264 (1996)
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Introduction
Benzene, a widely used industrial chemical exposed humans (1-4). Benzene hemato-
and ubiquitous environmental pollutant, is toxicity occurs when its hepatic metabolites
a Class I carcinogen that causes acute myel- (5,6), phenol, catechol, and hydroquinone
ogenous leukemia (AML) in chronically (HQ), are transported to the bone marrow
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(7,8) and further oxidized in a peroxidase-
mediated (9-11) reaction to biologically
reactive intermediates that can potentially
affect hematopoiesis. An increased inci-
dence ofAML is associated with benzene
exposure; therefore, it is important to
determine whether benzene or any of its
metabolites (such as HQ) directly affects
the stem cell or progenitor cells of the
myeloid lineage. The ability to alter
cytokine-dependent growth and differentia-
tion in hematopoietic progenitor cells
appears to be a property of many agents
with leukemogenic potential for humans
(12). Several studies have reported signi-
ficant effects ofbenzene on hematopoietic
stem and progenitor cells (13). In one study
(14), a dose-dependent depression of all
stem cell compartments was observed in
BDF1 mice exposed for 16 weeks to air-
borne concentrations ofbenzene as high as
99 ppm for 6 hr/day, 5 days/week. The
results of this study indicated that the
granulocyte/macrophage colony-forming
unit (GM-CFU) was much less sensitive
than the erythroid CFUs at higher doses of
benzene. Another study (15) reported that
short-term exposure of mice to benzene
induced a shift toward granulocytic differ-
entiation, a growth advantage for granulo-
cytic progenitor cells in the bone marrow
and spleen, and to a resultant increase in
the total number of granulocytes. These
results suggest that benzene or HQ is act-
ing on the myeloid stem or progenitor
cells. We report here that the administra-
tion ofbenzene, or HQ, specifically stimu-
lates granulopoiesis in mice and induces
granulocytic differentiation in myeloblasts
ofthe human promyelocytic leukemia cell
line, HL-60, as well as the normal murine
interleukin 3 (IL-3)-dependent myeloblastic
cell line, 32D.3 (G). Benzene and HQ do
this by replacing the requirement for granu-
locyte colony-stimulating factor (G-CSF)
and leukotriene D4 (LTD4), respectively,
for induction ofdifferentiation.
Methods
Culture ofCells and Exposure to HQ,
Benzene, G-CSF, LTD4, andOtherAgents.
HL-60 human promyelocytic leukemia
cells (ATCC #240-CCL, Rockville, MD)
were cultured at 37°C, 5% CO2 in RPMI
1640 medium (Mediatech, Washington,
DC) supplemented with 2 mM glutamine
and 10% fetal bovine serum (FBS). Cells
(5x 105/ml), from passages 18 to 42, were
treated with or without benzene in RPMI
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Table 1. Morphological examination of benzene-induced granulocytic differentiation in HL-60 cells.
Cell type percentage
Mature Total
System Myelobast Promyelocyte Myelocyte Metamyelocyte granulocyte granulocytes
HL-60 36 45 2 15 2 19
HL-60 + 15 29 16 30 10 56
5 mM benzene
Cells were treated with benzene as described for Figure 4. Morphological examination was performed by Cytospin
preparation and May-Grunwald/Giemsa staining. Percentages were based on the average obtained by counting
200 cells on each oftriplicate slides in six experiments.
1640/2 mM glutamine/10% FBS for 7 days
at 37°C, after which differentiation to gran-
ulocytes was assessed. Because ofbenzene's
volatility, cells were treated with benzene in
microsomes with teflon-lined screw caps
and very small head space. LTD4 was added
directly to the culture medium (see Table 1
and figure legends for concentrations used).
The 5-lipoxygenase (LPO) inhibitors and
LTD4 receptor antagonists were also added
directly to the culture medium, or concen-
trations used), but 20 min prior to the addi-
tion ofthe inducing agent.
The IL-3-dependent myeloblastic cell
line, 32D.3, derived from normal bone
marrow of C3H/HeJ mice, has a normal
karyotype and is nonleukemic (16). The
clone was previously characterized for
IL-3-dependence (17) and for G-CSF
induction ofdifferentiation [32D.3 (G)]
(18). 32D.3 (G) cells were maintained in
Iscove's modified Dulbecco's medium
(IMDM) with 2 mM glutamine/10% FBS
and 3 U/ml recombinant murine IL-3
(rMuIL-3) at 37°C, 5% CO2. 32D cells
(2.5 x 105/ml) in IMDM/2 mM gluta-
mine/10% FBS were treated with or
without benzene and with or without 3
U/ml rMuIL-3. When HQ was used, the
cells were pretreated with 2 pM HQ in
Dulbecco's phosphate-buffered saline minus
Ca2+ and Mg2+ (PBS)/2 mM glucose [PBS-
A] for 30 min at 37°C, afterwhich the cells
were collected, washed twice with PBS,
and placed into culture in IMDM/2 mM
glutamine/10% FBS with or without 3
U/ml rMuIL-3. LTD4 [as well as recombi-
nant human G-CSF (rHuG-CSF)], the
LPO inhibitors, and the LTD4 receptor
antagonists were added as for HL-60 cells,
but in the presence or absence of IL-3.
Unless otherwise indicated (in figure or
table legends), a sample ofeach culture was
removed for cell counting after 3 days of
incubation, and the remainder ofthe culture
diluted to 2.5 x 105 cells/ml to ensure opti-
mal growth conditions. Incubation was con-
tinued for 4 days, after which the cells were
analyzed for the granulocytic phenotype.
Assessment of Differentiation.
Granulocytic differentiation was assessed
by four factors: the acquisition ofgranulo-
cytic morphology-specifically promyelo-
cytes, myelocytes, metamyelocytes, and
mature segmented cells; the development
ofsuperoxide production-as measured by
the reduction of nitroblue tetrazoleum
(NBT); the development of chloroacetate
esterase activity; and, in the case ofHL-60
cells, the appearance ofthe L-12-2 granulo-
cyte-specific surface antigen. Morpholog-
ical assessment of differentiation was
performed by Cytospin preparation
(Shandon Scientific Ltd, Pittsburgh, PA)
and May-Griinwald/Giemsa staining
(Sigma Chemical Co, St. Louis, MO).
Percentages were based on the average
obtained by counting 200 cells on each of
triplicate slides. For NBT reduction, cells
were incubated for 1 hr with 0.125
nmol/liter 12-O-tetradecanoyl-phorbol-13-
acetate (TPA) and 0.05% NBT. Cells were
fixed on a slide, counterstained with
safranin, and the percentage of cells con-
taining black granules ofreduced NBT was
determined. Chloroacetate esterase activity
was determined by incubating fixed cells
with a diazonium salt, AS-D chloroacetate,
and Red Violet at pH 6.3 for 5 min at
37°C, after which the percentage of cells
containing red granules was determined.
The presence ofL-12-2 surface antigen was
detected by fluorescence microscopy using
rhodamine-labeled antimouse immuno-
globulin against the monoclonal antibody.
Treatment ofAnimals with Benzene
and HQ. Inbred C57BL/6J male mice
(22-25 g) received benzene (600 mg/kg bw)
in corn oil or HQ (25 or 50 mg/kg bw) in
PBS ip, twice per day, 7 hr apart, for 2 days.
Controls received corn oil or PBS. Eighteen
hours after the final injection, the animals
were killed by cervical dislocation, their
femurs removed, and the bone marrow cells
obtained (as described below).
Determination of Bone Marrow
Cellularity andMorphologic Hematology.
The epiphysial plate on each end of the
femur was removed and the femur was
flushed with 1 ml of 100% FBS using a
syringe with a 25-gauge needle. The mar-
row was collected in a tissue culture tube
and a single cell suspension prepared by
passing the marrow through the syringe two
additional times. A sample (100 pi) ofthe
cell suspension was used to prepare slides,
which were then stained (as described
below) and used for differential cell counts.
The remainder of the cell suspension was
diluted in cold lysing buffer (10 mM Tris
HCI, pH 7.4, 155 mmol/liter NH4CI) to
remove red blood cells, and the number of
nucleated cells was determined by hemocy-
tometer. Viability was tested by Trypan
Blue exclusion and was always > 98%.
Staining was carried out as follows: the
slides were dipped in Wright stain (Hema
Quik II) (Curtin Matheson, Houston, TX)
for 3 min, washed in tap water for 3 min,
and allowed to air dry for at least 30 min.
Counterstaining was carried out for 7 min
in Giemsa (Azure B Type) prepared fresh
as a 1:50 dilution in Hydrion buffer, pH
6.8. The slides were then washed for 30 sec
under running tap water and allowed to air
dry. Differential cell counts were carried
out under oil immersion at 100 times. Five
hundred cells per slide were counted and
the percentage of cells at each stage of
differentiation was determined.
StatisticalAnalysis. Data between
groups were analyzed using the Student's
t-test, or ANOVA followed by Dunnett's
t-test. Results are expressed as mean values
± SD. Ap<0.01 was considered significant.
Results
Stimulation ofGranulocytic
Differentiatlon inMice
byBenzene andHydroquinone
As can be seen in Figure 1, ip treatment of
mice with benzene results in an overall
depression of bone marrow cellularity
selective for the lymphoid and erythroid
lineages, while the granulocytic lineages
actually show an increase in cell number
and a shift toward granulocytic differentia-
tion. These results directly support those
previously obtained by Seidel (14), and
Dempster and Snyder (15). A more in-
depth examination of the effects of ben-
zene (and its metabolite HQ) on the
induction ofgranulocytic differentiation in
mice (Figure 2) indicated that benzene was
able to stimulate the differentiation of
myeloblasts, as measured by an increase in
the percent ofpromyelocytes and interme-
diate granulocytic progenitors in the bone
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marrow one day after the last benzene
injection (3 days after the initiation of
treatment), but had no effect on the num-
ber of myeloblasts. Neither was the num-
ber of mature granulocytes stimulated by
day 3. However, in experiments carried out
for 7 days, benzene significantly increased
the number of mature granulocytes com-
pared to control values (Figure 3). The
experiments presented here are representa-
tive of three such experiments each, all of
which gave similar results. Identical results
were obtained when the data were expressed
as percentage oftotal cells counted. Hydro-
quinone administered to mice for 3 days, at
a dose of 50 mg/kg bw, also stimulated
granulocytic differentiation as indicated by
an increased percentage of promyelocytes
and intermediate granulocytic progenitors
(Figure 2). In contrast to benzene, HQdou-
bled the number ofmyeloblasts and stimu-
lated differentiation to GB forms to a
greater extent than benzene, yet the terminal
differentiation of GB to mature granulo-
cytes was limited. HQ administered at 25
mg/kg body weight caused a lesser, but
significant, stimulation ofgranulopoiesis
(data not shown). At these doses ofbenzene
or HQ, there was no loss of animals, nor
any overt signs oftoxicity, and the viability
of the cells flushed from the femurs was
always >98%.
Granulocytic Differentiation
ofMycloblasts byBenzene
andHydroquinone
These in vivo results suggested that ben-
zene per se, or by its metabolism to HQ, is
capable ofinducing granulocytic differenti-
ation. However, these results do not indi-
cate whether either compound causes
induction directly or indirectly in vivo. To
answer this question and to develop a sys-
tem for use in further mechanistic studies
involving the induction ofgranulocytic dif-
ferentiation, we turned to the use of
myeloid cell lines. The well-studied human
promyelocytic leukemia cell line, HL-60
(19), which consists of approximately 35
to 45% myeloblasts and 55 to 65% pro-
myelocytes, was selected because it has
been used in many studies as a surrogate
for the GM-CFU and because a number of
agents have been shown to induce terminal
granulocytic differentiation in these cells
(19). The normal IL-3-dependent mouse
myeloblastic 32D.3 (G) cell line was cho-
sen because it has been adapted to termi-
nally differentiate to granulocytes in
response to G-CSF (18) and because any
data obtained using this cell line can be
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Figure 1. Benzene-induced selective depression of bone
marrow cellularity in C57BL/6J mice. Groups (n=4) of
male C57BL/6J mice were established. One group
served as the control and received only corn oil. The
other groups were injected ip with benzene (600 mg/kg
bw) in corn oil twice per day, 7 hr apart, for 2 days.
Eighteen hours afterthe final injection, the animals were
sacrificed by cervical dislocation, their femurs removed,
and the nucleated bone marrow cells obtained and
counted as described under methods. An analysis of the
total numbers of cells ofthe various lineages in the bone
marrow was carried out. A sample of the bone marrow
cell suspension was used to prepare a slide for differen-
tial count. The slide was stained and analyzed as
described under methods. For each slide 500 cells were
counted and the percentage of each cell type deter-
mined. This percentage was multiplied bythe total num-
ber ofcells perfemurto determinethe numberofa given
cell type, and that was normalized to the number of cells
in the control group. Data are expressed as the mean
±SD (n=4). Where there were differences between
groups, theywere significant atthe p 0.01 level. Lymph,
lymphocytes; NEC, nucleated erythroid cells; PM,
promyelocytes; Neutr, neutrophils; Eos, eosinophils.
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Figure 2. The induction of granulocytic differentiation
in C57BL/6J mice by benzene or HQ. Groups of mice
(n=4) were injected with benzene (600 mg/kg bw) in
corn oil or HQ(50 mg/kg bw) in PBS-A, twice daily for 2
days. The control animals received corn oil or PBS-A
only. Eighteen hours after the final injection, the mice
were killed and their bone marrow obtained. A morpho-
logical analysis of the bone marrow was carried out as
described under methods. Data are presented as
absolute numbers of myeloid cells per femur repre-
sented by blast cells and total granulocytic cells of 500
cells analyzed. Qualitatively similar results were
obtained when the data were expressed as the percent
of nucleated bone marrow cells. The results are
expressed as the mean ±SD (n=4); *p<0.001 as com-
pared with the control group. The data for various cell
types from the individual marrows are extremely tight
(they range from SD ± 0.001 to ±0.03) and too small to
be plotted by the printer/plotter; therefore, no error
bars are visible. PM, promyelocytes; GB, myelocytes,
metamyelocytes, and band (ring) forms; GS, segmented
mature granulocytes.
PM GB GS PM GB GS PM GB GS
Day3 Day5 Day7
Figure 3. The induction of granulocytic differentiation in C57BL/6J mice by benzene over time. Groups of mice
(n=4) were treated with benzene as described for Figures 1 and 2. Several groups were sacrificed, and their nucle-
ated bone marrow cells harvested, 18 hr after the last benzene injection (3 days after the initiation of treatment)
as before. However, several other groups were maintained for an additional 2 days and then sacrificed (5 days
after treatment initiation), and still other groups were maintained for 2 more days before being sacrificed (7 days
after treatment initiation). All total and differential counts were determined as for Figures 1 and 2. PM, promyelo-
cytes; GB, myelocytes, metamyelocytes, and band(ring) forms; GS, mature segmented granulocytes.
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directly compared with that obtained from
the mouse.
Benzene-inducedGranulocytic
Differentiation in HL-60 Cells
As can be seen from the data presented in
Table 1 and Figure 4, exposure of HL-60
myeloblasts to benzene, followed by incu-
bation for 7 days, resulted in terminal
granulocytic differentiation as measured by
morphology (determination ofthe percent
of cells classified as myelocytes or higher
granulocytic forms) and the development
ofseveral characteristics ofthe granulocytic
phenotype. No significant induction of
nonspecific esterase activity (Figure 4),
indicative ofmonocytes, was detected, nor
was monocyte morphology observed
(Table 1). The ability ofbenzene to induce
granulocytic morphology, as well as the
appearance ofother markers ofthe granu-
locytic phenotype, was a function of the
concentration of benzene used over the
range of 0.1 mM to 5 mM (data not
shown). As can be seen in Table 1, benzene
treatment of HL-60 cells caused a signi-
ficant decrease in the number ofnormally
occurring myeloblasts and promyelocytes
with a corresponding shift toward more
intermediate progenitors and mature gran-
ulocytes. The majority ofthe differentiated
progenitors appeared to be metamyelocytes
and myelocytes, but a significant number of
terminally differentiated granulocytes was
observed (Table 1).
InvolvementofProtein Kinase C
andthe 5-LPO Pathwayin Benzene-
inducedGranulocytic Differentiation
ofHL-60 Cells
Sustained activation of protein kinase C
(PKC) is essential to the induction ofdiffer-
entiation in HL-60 cells (20). Both retinoic
acid and dimethylsulfoxide (DMSO) induce
HL-60 cells to differentiate to granulocytes
by activation ofPKC (21). Benzene acti-
vates PKC in intact rabbit platelets (22)
and in the macrophagelike cell lines,
P388D1 and BAC1.2F5CSF-1 (Carlson
and Kalf, unpublished data). An indica-
tion that benzene also activates PKC in
HL-60 cells is provided by the benzene-
induced phosphorylation of cellular pro-
teins in these cells, as well as the ability of
benzene-treated HL-60 cell membrane
preparations to carry out the phosphoryla-
tion ofhistone III-S, a PKC substrate, in
an in vitro assay (23,24). Sphinganine, a
potent inhibitor of PKC in vitro and in
cell systems (25), prevents not only ben-
zene-induced phosphorylation of cellular
proteins, but also differentiation to granu-
locytes (23,24), implicating the phospho-
rylation of these proteins by PKC in
benzene-induced granulocytic differentia-
tion ofHL-60 cells.
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An active LPO pathway ofmetabolism
that converts arachidonic acid (AA) to the
peptidoleukotriene, LTD4, is essential for
normal (26,27) as well as leukemic (28,29)
myeloid progenitor cell differentiation.
LTD4 is an essential intermediate in
CSF-induced clonal growth ofGM-CFU
(26,27). It has been demonstrated that HL-
60 cells express a granulocytic phenotype if,
during induction, PKC-activated release of
AA from plasma membranes, and lipoxy-
genation ofAA to LTD4, occurs (26).
Benzene-treatment ofHL-60 cells results in
a release ofAA from membrane lipids and a
subsequent increase in LTD4, both ofwhich
are inhibited bysphinganine (23,24).
Several inhibitors of5-LPO were tested
for their ability to prevent benzene-induced
granulocytic differentiation ofHL-60 cells
as measured by morphology and a func-
tional parameter, superoxide production
(NBT reduction). From Table 2 it is appar-
ent that the highly specific 5-LPO inhi-
bitor, AA-861 (30), as well as caffeic acid,
prevented benzene-induced granulocytic
differentiation and that this inhibition
could be overcome by the concomitant
addition ofLTD4 to the reaction. To fur-
ther implicate LTD4 in the differentiation
process, we tested the ability of LTD4
receptor antagonists to inhibit benzene-
induced differentiation. HL-60 cells were
incubated with benzene in the presence or
absence of MK-571, a highly specific
inhibitor of LTD4 binding to its high
affinity receptor (31). Benzene-induced
Table 2. Effects of AA-861 and caffeic acid on ben-
zene-induced granulocytic differentiation in HL-60
cells.
Percentage of cells counted
System Morphology NBT reduction
Control 12.3 ± 5.5 16.7 ± 3.5
+ Benzene 37.5 ± 3.8* 45.7 ± 3.3*
+ Benzene/caffeic acid 17.5 ± 3.9 20.8 ± 3.7
+ Benzene/caffeic acid/ 37.7 ± 3.7** 42.8 ± 8.3**
LTD4
+ Benzene/AA-861 23.7 ± 3.3 18.3 ± 1.7
+ Benzene/AA-861/ 54.7 ± 10.5** 28.7 ± 4.1**
LTD4
*Significantly different from control and benzene-
treated cells pretreated with inhibitors. **Significantly
different from cells treated with benzene and
Morphology NBT Chloracetate L-12-2 Nonspecific inhibitors. p<0.01. Cells (5x105/ml) were preincu-
reduction esterase antigen esterase bated in culture with the 5-LPO inhibitors, caffeic acid
(100 pM) or AA-861 (1 pM), and with LTD4 (1 pM) in
zene-induced granulocytic differentiation of HL-60 myeloblasts. Cells (5x105/ml) were cultured with, RPMI 1640/10% FBS for 10 min at 37°C, 5% CO2.
mM benzene, as described in the methods section, for up to 7 days. The development of the granu- Benzene (5 mM) was added directly to the culture and
type was determined by measuring those characteristics presented in the figure. Each analysis was NBT reduction and granulocytic differentiation were
described in the methods section; each set of values represents the mean ±SD of three experi- determined after incubation for 7 days. Values repre-
each sample was carried out intriplicate. * Significantly different from the control cells atp <0.001. sentthe mean ±SD of at least twoexperiments carried
Hazel et al. (24)with permission ofAlphaMed Press. out intriplicate.
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granulocytic differentiation ofHL-60 cells
was completely inhibited by the LTD4
receptor antagonist and differentiation was
restored by the addition of excess LTD4
(Figure 5). Another receptor antagonist,
LY163443 (32), gave similar results (data
not shown). Taken together, these results
indicate that both production ofLTD4, and
its interaction with, and activation of, its
receptor are essential for benzene-induced
granulocytic differentiation.
Granulocytic Differentiaton ofthe
Myeloblastic Celi Line 32D.3 (G)
byBenzene andHydroquinone
To compare the induction ofgranulocytic
differentiation by benzene and HQ with
that of the normal physiological inducer,
G-CSF, we turned to the IL-3 dependent
diploid myeloblastic cell line, 32D.3 (G),
which was derived from normal mouse
bone marrow and adapted to differentiate
in the presence of G-CSF (18). Table 3
presents data from one representative of
four experiments that gave similar results.
Few differentiated myeloid cells were
detected in the presence of IL-3 alone,
which, although obligatory for prolifera-
tion and survival of the myeloblast, does
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not induce differentiation. rHuG-CSF,
which is fully capable of binding to the
mouse G-CSF receptor, induced terminal
differentiation to granulocytes. Substitution
ofnoncytotoxic concentrations ofbenzene
or HQ in place ofG-CSF also induced dif-
ferentiation in 32D myeloblasts (Table 3).
While both benzene and HQ replaced the
necessity of G-CSF for differentiation to
granulocytes, neither was able to obviate
the dependence of the cells on IL-3 for
survival and growth (data not shown).
GranulocyticDifferentiation
of32DMyeloblasts byLTD4
Since LTD4 is a downstream effector of
G-CSF-induced signal transduction and
benzene has been shown to produce LTD4
via activation of PKC with subsequent
release ofAA (23,24) and upregulation of
the 5-LPO pathway (Table 2), we tested
the ability ofLTD4 to replace either G-CSF
or benzene (as well as HQ) in the induction
of granulocytic differentiation in 32D
myeloblasts. As can be seen in Figure 6,
LTD4 is capable ofreplacing these inducing
agents in the concentration-dependent
induction of terminal differentiation in
32D myeloblasts.
Effects of5-LPO Inhibitors andLTD4
ReceptorAntagonists ontheAbilityof
Hydroquinone to Induce Granulocytic
Differentiation in 32D Myeloblasts
The induction ofdifferentiation by G-CSF
(Table 4A) and benzene (data not shown)
Table 3. Induction of granulocytic differentiation in
32D cells by benzene and HQ.
Percentage of cells counted
System Morphology NBT reduction
IL-3 7.5 ± 3.2 4.3 ± 0.6
+ G-CSF 30.8 ± 2.5 36.7 ± 1.7
+ Benzene 53.0 ± 1.0 55.0 ± 0.7
+ HQ 67.8 ±3.3 66.8 ±1.4
* * *I I * *I Cells (2.5x105/ml) were pretreated with HQ (2 PM in
NBTreduction Morphology PBS-A) or PBS-A for 30 min at 37°C. The cells were
harvested by centrifugation, suspended in IMDM
hibition of benzene-induced granulocytic (2.5x105/ml) containing 3 U/ml rMulL-3 and 10% FBS.
ion in HL-60 cells by an LTD4 receptor rHuG-CSF (0.15 ng/ml) or benzene (5 mM) was added
,ells (5x105/ml) were preincubated with 1 to the PBS-A-pretreated cells. Controls and HQ-pre-
in RPMI 1640/10% FBS for 10 min at treated cells received only PBS-A. After 3 days of cul-
2. Benzene (5 mM) was added and granu- ture at 37°C, 5% C02, the medium was changed and
ology was assessed after incubation for 7 the cells diluted to the original concentration to insure
represent the mean ±SD of two experi- optimal growth conditions. The incubation was contin-
*e each sample was carried out in tripli- ued for 4 more days, at which time parameters indica-
icantly different from the control cells at tive of granulocytic differentiation were assessed. The
level; **significantly different from cells values listed represent the mean ±SD of the results of
benzene and MK-571, but not significantly triplicate wells. Data are presented as the percentage
m cells treated with benzene only, at the of cells showing granulocytic differentiation (promyelo-
31. Reprinted from Hazel et al. (24) with cytes to mature segmented granulocytes) of a total of
AlphaMed Press. 200 cells counted.
is inhibited by a specific 5-LPO inhibitor,
as expected, since both G-CSF (33) and
benzene induce the release ofAA (the sub-
strate for 5-LPO) from plasma membranes
(23,24). However, the ability of HQ to
induce differentiation is not prevented by
the 5-LPO inhibitor, suggesting that HQ,
in contrast to G-CSF and benzene, does
not induce the formation of LTD4, but
rather functions in some otherway, perhaps
by interacting with the LTD4 receptor.
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Figure 6. LTD4-induced granulocytic differentiation in
32D myeloblasts. Cells (2.5x105/ml) in IMDM (3 U/ml
rMulL-3; 10% FBS) were incubated with orwithout LTD4
for 3 days at 37°C, 5% C02. Cells were thinned to the
original cell number/ml and incubated an additional 3
days without the further addition of LTD4. Cytospin
slides were stained for morphological analysis using
May-GrOnwald/Giemsa stain. Cells were monitored for
superoxide production by following NBT reduction using
TPA/NBT, as described in the methods section, and
counterstaining with Safranin. Reprinted from Hazel et
al. (24)with permission ofAlphaMed Press.
Table 4. Effects of AA-861 and MK-571 on G-CSF- and
HO-induced differentiation of 32D cells.
Percentage ofcells counted
System Morphology NBT reduction
A.
Control 17.5 ± 2.6 12.5 ± 3.6
+G-CSF 70.8 ± 3.5 48.2 ± 10.6
+G-CSF/AA-861 31.9 ± 0.9 12.6 ± 2.4
+HQ 81.5 ± 1.3 48.6± 5.7
+HQ/AA-861 66.1 ± 1.7 38.6 ± 2.0
B.
Control 17.5 ± 2.6 12.5± 3.6
+G-CSF 70.8 ± 3.5 48.2 ± 16.6
+G-CSF/MK-571 32.8 ± 8.8 26.8 ± 6.2
+HQ 81.5± 1.3 48.6± 5.7
+HQ/MK-571 24.1 ±1.8 15.2±2.5
Cells (2.5x105/ml) were pretreated with a final con-
centration of 2 pM HQ or treated with rHuG-CSF (0.15
ng/ml) as described in Table 3. The 5-LPO inhibitor AA-
861 or the LTD4 receptor antagonist MK-571 was
added to each sample at 1-pM final concentrations.
Morphological analysis was performed as described
forTable 3.
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Therefore, we carried out an experiment to
ascertain whether the ability of HQ to
induce terminal granulocytic differentia-
tion in 32D myeloblasts could be pre-
vented by an LTD4 receptor antagonist.
The addition of the specific antagonist
MK-571 completely blocked HQ-induced
terminal granulocytic differentiation
(Table 4B) indicating that HQ may inter-
act with the ligand-binding domain of the
receptor to activate its signal and initiate
the cascade ofevents that result in granulo-
cytic differentiation. Hydroquinone can be
oxidized in the cell to p-benzoquinone
(BQ), a bifunctional alkylating agent that
can interact indiscriminately with available
sulfhydryl groups on membrane-bound
proteins (4,34). Therefore, the possibility
exists that BQ may bind covalently to
sulfhydryl groups located at, or very near,
the ligand-binding domain of the LTD4
receptor, obviating the need for LTD4 and
activating the receptor in a constitutive,
rather than signal-driven manner (as is the
case with LTD4).
Effects ofLTD4 versus HQ
on 32D MyeloblastProliferation
andGranulocytic Differentiation
The indication from LTD4 receptor antag-
onist studies that HQ, like LTD4, induces
granulocytic differentiation through direct
interaction with, and activation of, the
LTD4 receptor was an interesting one. To
further study this phenomenon, we exam-
ined the effects ofboth LTD4 and HQ on
32D cell proliferation and differentiation,
in the presence and absence of IL-3, over
time. As can be seen in Figure 7, neither
LTD4 nor HQ can induce a signal for
proliferation in 32D myeloblasts in the
absence of IL-3. However, in the presence
of IL-3, both LTD4 and HQ showed a
significant stimulation of cell growth
which, in the case of HQ, was more than
100% at day 4. LTD4 and HQ were both
also capable oftransmitting a signal for dif-
ferentiation in the presence (data not
shown) or absence ofIL-3 (Figure 8). In the
presence of the minimal concentration
(3 U/ml) ofIL-3 required for survival and
proliferation of 32D myeloblasts, each
inducer caused 100% total differentiation,
but the degree of terminal differentiation
was delayed in comparison with cells grown
in the absence of IL-3 (data not shown).
The proliferative signal provided by IL-3
competes with the differentiation signal
from the inducer such that the degree of
both total and terminal differentiation is
decreased at 6 days.
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An analysis of the kinetics of stage-
specific granulocytic differentiation was
performed on 32D myeloblasts induced by
LTD4 or HQ in the absence ofIL-3. This
allowed for a determination ofthe induc-
tive effects ofLTD4, or HQ, in the absence
ofany competitive proliferative signal from
IL-3. Figure 8 demonstrates that LTD4
was incapable of providing a proliferative
signal, as evidenced by the low number of
promyelocytes detected over the 6-day
period, but was capable of producing a
significant number ofterminally differenti-
ated granulocytes, as well as an increased
number of intermediate progenitors. At
each time point examined, the predomi-
nate cell type (differentiation stage) present
was the mature segmented granulocyte.
Absence of a proliferative burst was also
detected upon HQ treatment; but, unlike
LTD4, HQ induced predominately myelo-
cytes at any given time point (Figure 8).
HQ appears unable to induce significant
differentiation beyond this point and,
therefore, results in an incomplete differen-
tiation program in these cells.
Discussion
Exposure of C57BL/6J mice to a dose of
benzene (35) known to depress other
hematopoietic cell lineages (Figure 1)
significantly stimulated granulocytic differ-
entiation as well as the total number of
granulocytes, indicating that granulopoiesis
Day2 Day4 Day 6
Figure 8. Profile of stage-specific differentiation
induced by LTD4 and HQ treatment of 32D cells in the
absence of IL-3. Cells (2.5x105/ml) were treated with
LTD4 or HQ in the absence of IL-3, as described for
Figure 7. Samples of each culture were collected every
second day and Cytospin preparations made and
stained using May-Grunwald/Giemsa as described in
the methods section. Morphologic analysis and deter-
mination of the percentages for stage-specific differen-
tiation were performed by counting 200 cells on each
oftriplicate slides per sample and determining an aver-
age percentage of cells at each stage of differentia-
tion. Percentage of total differentiation was calculated
by totaling the percentages of stage-specific differenti-
ation for each sample. P, promyelocytes; My, myelo-
cytes; M, metamyelocytes; and Ma, mature segmented
granulocytes.
was also occuring (Figure 2). While ben-
zene could not provide a growth signal for
myeloblasts, it did stimulate their differen-
tiation to promyelocytes and intermediate
progenitors, but did not stimulate the pro-
duction of mature granulocytes by day 3.
However, when measured at day 7, ben-
zene had increased the number of seg-
mented mature granulocytes (Figure 3).
Our results show a general increase in gran-
ulocytes after benzene exposure and are
consistent with those that show an increase
in the number of granulocytes in bone
marrow of DBA/2J mice after short-term
exposure to benzene (15). Hydroquinone,
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a major metabolite ofbenzene found in the
bone marrow, also stimulated proliferation
and differentiation ofgranulocytic progeni-
tor cells by day 3 when administered to
C57BL/6J mice (Figure 2) as well as in
mouse 32D myeloblasts in culture (Figures
7, 8). In contrast to benzene, HQprovided
both proliferative and differentiative signals
for myeloblasts in vivo that increased the
numbers of all progenitor forms, but
appeared incapable of inducing terminal
differentiation (Figure 2) for reasons that
are not yet clear.
To study the mechanism(s) whereby
benzene and HQ stimulate granulopoiesis,
we investigated whether the inductive effect
ofbenzene or HQon granulocytic differen-
tiation could be reproduced in myeloblasts
in culture. Benzene at noncytotoxic concen-
trations caused a dose-dependent specific
induction of terminal granulocytic differ-
entiation in HL-60 myeloblasts (Table 1;
Figure 4), as measured by morphological
and functional parameters (superoxide pro-
duction, chloroacetate esterase activity, and
the appearance of the specific surface anti-
gen L-12-2) that are specific for granulo-
cytic differentiation. Benzene induction
produced a majority of intermediate prog-
enitors (myelocytes, metamyelocytes and
band forms); however, a significant num-
ber of mature granulocytes were also
observed (Table 1). These results corre-
spond to earlier observations that the gran-
ulocytic differentiation of HL-60 cells
induced by certain agents is somewhat
incomplete and defective (19).
As was previously shown, activation of
PKC appears to be involved in the induc-
tion ofgranulocytic differentiation in ben-
zene-treated HL-60 myeloblasts. This is
because the phosphorylation of cellular
proteins, as well as the induced differentia-
tion, was prevented by the concomitant
presence of benzene and the specific PKC
inhibitor sphinganine (23,24). Benzene-
induced differentiation of HL-60 myelo-
blasts to granulocytes also appears to involve
the induction of a functioning 5-LPO
pathway for production of LTD4, since
differentiation is inhibited by the 5-LPO
inhibitors caffeic acid and AA-861 (Table
2) and by the specific LTD4 receptor
antagonist, MK-571 (Figure 5). Inhibition
by each of these agents was prevented by
the concomitant addition ofLTD4. These
results together support the view that a role
for benzene in the induction ofgranulo-
cytic differentiation in HL-60 myelo-
blasts-like that ofG-CSF-is to produce
LTD4, which is a necessary signal for
granulocytic differentiation. Although G-
CSF has not yet been demonstrated to
directly cause the production of LTD4, it
has been shown to cause the activation of
phospholipase A2 and the subsequent
release ofAA from cell membranes (33).
Benzene is also capable of inducing
granulocytic differentiation in the diploid
IL-3-dependent murine myeloblastic cell
line, 32D.3 (G), whereas IL-3 induces only
a growth response (Table 3). rHuG-CSF
provides not only a differentiation signal
(Table 3), but, in the absence of IL-3, a
growth signal for 32D myeloblasts as well
(24). Benzene, unlike G-CSF, is incapable
ofinducing growth in the absence of IL-3,
but does provide the differentiation signal,
and neither G-CSF nor benzene can syner-
gize with IL-3 to stimulate growth (24).
LTD4 and HQ are also incapable ofsup-
porting growth of32D cells in the absence
of IL-3, but can synergize with IL-3 to
enhance growth (Figure 7). Both LTD4
and HQ induce granulocytic differentia-
tion in 32D myeloblasts (Figure 8). Either
benzene or HQ (Table 3), as well as LTD4
(Figure 6), can replace G-CSF for induc-
tion of differentiation. Note that, in the
experiment reported in Table 3, no effort
was made to optimize concentrations, so
that the magnitude of benzene- or HQ-
induced differentiation cannot be quantita-
tively compared with that ofG-CSF. These
results, in total, indicate that benzene, with
its metabolite HQ, can induce granu-
lopoiesis in 32D mouse myeloblasts since
both the number of progenitor cells and
terminally differentiated granulocytes
increased; and they support our in vivo
results concerning the induction ofgranu-
lopoiesis by benzene and HQ in mice
(Figure 2). The ability ofHQ to synergize
with other cytokines/growth factors (as
seen in Figure 7 for IL-3) has been
previously documented. Irons et al. (36),
showed that pretreatment of nonadherent
murine bone marrow cells, or lineage-
restricted hematopoietic cells, with HQ, in
vitro, followed by culture in complete
medium for 8 days, significantly enhanced
the number ofgranulocyte-macrophage
colonies induced by recombinant GM-CSF.
Optimal enhancement was observed with 1
pM HQ, was largely independent of the
concentration of GM-CSF, and was not
observed with other marrow metabolites
such as phenol or catechol.
The fact that benzene-induced granu-
locytic differentiation of myeloblasts
in culture is prevented by inhibitors of
PKC and 5-LPO supports the view that
benzene-induced differentiation might also
be due to benzene per se, not only the
result of its metabolism to HQ in the
myeloblast. Consequently, not all of the
granulopoietic activity ofbenzene in vivo
can be attributed to its metabolism to HQ.
During chronic benzene exposure, benzene
and HQare both present in the bone mar-
row; therefore both can contribute to gran-
ulocytic differentiation. On the basis of
results presented here and those previously
obtained in our laboratory, benzene, like
G-CSF, appears to activate the AA cascade
and upregulate the 5-LPO pathway for the
production of LTD4. Hydroquinone
appears to obviate the requirement for
LTD4 by activating the LTD4 receptor
directly since specific LTD4 receptor antag-
onists, but not 5-LPO inhibitors, prevent
HQ-induced granulocytic differentiation
in myeloblasts.
One can speculate about the roles of
benzene and HQ in benzene-induced
AML. As a known clastogen, HQ may
cause a leukemogenic initiating event in the
myeloblast [i.e., one ofthe translocations or
deletions characteristic ofAML (4)], and at
the same time covalently bind to the LTD4
receptor to constitutively activate this sig-
nal-driven process and induce granulocytic
differentiation, which is incomplete and
arrested at the myelocyte stage. Blocks in
the developmental program of terminal
hematopoietic cell differentiation appear to
be a major step in tumor progression (37).
The ability of HQ to stimulate an increase
in the number ofmyeloblasts, both in vivo
(Figure 2) and in vitro (Figure 7) by an as
yet undetermined mechanism, may then
result in the dassic picture ofAML: an over-
proliferation ofincompletely differentiated
myeloid cells. Concomitantly, benzene may
provide a promotional effect on the initiated
myeloblast, via constitutive activation of
PKC, and overexpression ofits activity, with
resultant pleotropic effects on morphology
and growth control.
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